Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux-Reference-Cited by-同舟云学术

Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux

Published:2009-10 Issue:10 Volume:50 Page:2046-2054
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Vrins Carlos L.J.,van der Velde Astrid E.,van den Oever Karin,Levels Johannes H.M.,Huet Stephane,Oude Elferink Ronald P.J.,Kuipers Folkert,Groen Albert K.

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference39 articles.

1. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology;Lemberger;Annu. Rev. Cell Dev. Biol.,1996

2. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors;Dreyer;Cell.,1992

3. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression;Gulick;Proc. Natl. Acad. Sci. USA.,1994

4. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids;Rodriguez;J. Biol. Chem.,1994

5. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene;Tugwood;EMBO J.,1992

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mung bean protein pre-fibrils are superior than the mature fibrils in stabilizing HIPEs and controlling the lipid digestion to inhibit in vivo adipose accumulation;Food Hydrocolloids;2025-01

2. Diet predisposes to pancreatic cancer through cellular nutrient sensing pathways;FEBS Letters;2024-06-17

3. Fisetin, a dietary flavonoid, promotes transintestinal cholesterol excretion through the activation of PPARδ;Food Research International;2024-01

4. Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn’s Disease and Ulcerative Colitis Compared With Healthy Control Individuals;Inflammatory Bowel Diseases;2023-12-29

5. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis;Alimentary Pharmacology & Therapeutics;2023-10-30